151 related articles for article (PubMed ID: 26363191)
1. L-DOPA modulates cell viability through the ERK-c-Jun system in PC12 and dopaminergic neuronal cells.
Park KH; Shin KS; Zhao TT; Park HJ; Lee KE; Lee MK
Neuropharmacology; 2016 Feb; 101():87-97. PubMed ID: 26363191
[TBL] [Abstract][Full Text] [Related]
2. Multiple treatments with L-3,4-dihydroxyphenylalanine modulate dopamine biosynthesis and neurotoxicity through the protein kinase A-transient extracellular signal-regulated kinase and exchange protein activation by cyclic AMP-sustained extracellular signal-regulated kinase signaling pathways.
Park KH; Park HJ; Shin KS; Lee MK
J Neurosci Res; 2014 Dec; 92(12):1746-56. PubMed ID: 25044243
[TBL] [Abstract][Full Text] [Related]
3. Effects of (-)-sesamin on 6-hydroxydopamine-induced neurotoxicity in PC12 cells and dopaminergic neuronal cells of Parkinson's disease rat models.
Park HJ; Zhao TT; Lee KS; Lee SH; Shin KS; Park KH; Choi HS; Lee MK
Neurochem Int; 2015; 83-84():19-27. PubMed ID: 25747493
[TBL] [Abstract][Full Text] [Related]
4. Repeated treatments with the D
Park HJ; Zhao TT; Park KH; Lee MK
Behav Brain Res; 2019 Jul; 367():166-175. PubMed ID: 30930179
[TBL] [Abstract][Full Text] [Related]
5. Modulation of PC12 cell viability by forskolin-induced cyclic AMP levels through ERK and JNK pathways: an implication for L-DOPA-induced cytotoxicity in nigrostriatal dopamine neurons.
Park KH; Park HJ; Shin KS; Choi HS; Kai M; Lee MK
Toxicol Sci; 2012 Jul; 128(1):247-57. PubMed ID: 22539619
[TBL] [Abstract][Full Text] [Related]
6. The roles of cyclic AMP-ERK-Bad signaling pathways on 6-hydroxydopamine-induced cell survival and death in PC12 cells.
Park HJ; Park KH; Shin KS; Lee MK
Toxicol In Vitro; 2013 Dec; 27(8):2233-41. PubMed ID: 24055892
[TBL] [Abstract][Full Text] [Related]
7. 1-
Park HJ; Kang JK; Lee MK
Molecules; 2019 Mar; 24(5):. PubMed ID: 30823626
[TBL] [Abstract][Full Text] [Related]
8. Intranigral administration of substance P receptor antagonist attenuated levodopa-induced dyskinesia in a rat model of Parkinson's disease.
Yang X; Zhao H; Shi H; Wang X; Zhang S; Zhang Z; Zu J; Zhang W; Shen X; Cui G; Hua F
Exp Neurol; 2015 Sep; 271():168-74. PubMed ID: 26001615
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of L-DOPA-induced cytotoxicity in rat adrenal pheochromocytoma cells: implication of oxidative stress-related kinases and cyclic AMP.
Jin CM; Yang YJ; Huang HS; Kai M; Lee MK
Neuroscience; 2010 Oct; 170(2):390-8. PubMed ID: 20670675
[TBL] [Abstract][Full Text] [Related]
10. Effects of asarinin on dopamine biosynthesis and 6-hydroxydopamine-induced cytotoxicity in PC12 cells.
Park HJ; Lee KS; Zhao TT; Lee KE; Lee MK
Arch Pharm Res; 2017 May; 40(5):631-639. PubMed ID: 28397192
[TBL] [Abstract][Full Text] [Related]
11. Effects of gynosaponin TN-2 on L-DOPA-induced cytotoxicity in PC12 cells.
Shin KS; Park HJ; Park KH; Lee KS; Jeong SW; Hwang BY; Lee CK; Lee MK
Neuroreport; 2018 Jan; 29(1):1-5. PubMed ID: 29120941
[TBL] [Abstract][Full Text] [Related]
12. Gypenosides attenuate the development of L-DOPA-induced dyskinesia in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Shin KS; Zhao TT; Park KH; Park HJ; Hwang BY; Lee CK; Lee MK
BMC Neurosci; 2015 Apr; 16():23. PubMed ID: 25896846
[TBL] [Abstract][Full Text] [Related]
13. Persistent activation of the D1R/Shp-2/Erk1/2 pathway in l-DOPA-induced dyskinesia in the 6-hydroxy-dopamine rat model of Parkinson's disease.
Fiorentini C; Savoia P; Savoldi D; Barbon A; Missale C
Neurobiol Dis; 2013 Jun; 54():339-48. PubMed ID: 23328768
[TBL] [Abstract][Full Text] [Related]
14. Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat.
Henry B; Crossman AR; Brotchie JM
Exp Neurol; 1999 Feb; 155(2):204-20. PubMed ID: 10072296
[TBL] [Abstract][Full Text] [Related]
15. Ombuoside from Gynostemma pentaphyllum Protects PC12 Cells from L-DOPA-Induced Neurotoxicity.
Davaasambuu U; Park HJ; Park KH; Lee CK; Hwang BY; Lee MK
Planta Med; 2018 Sep; 84(14):1007-1012. PubMed ID: 29734446
[TBL] [Abstract][Full Text] [Related]
16. Behavioral and neurochemical effects of noradrenergic depletions with N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine in 6-hydroxydopamine-induced rat model of Parkinson's disease.
Srinivasan J; Schmidt WJ
Behav Brain Res; 2004 May; 151(1-2):191-9. PubMed ID: 15084435
[TBL] [Abstract][Full Text] [Related]
17. Selegiline normalizes, while l-DOPA sustains the increased number of dopamine neurons in the olfactory bulb in a 6-OHDA mouse model of Parkinson's disease.
Chiu WH; Carlsson T; Depboylu C; Höglinger GU; Oertel WH; Ries V
Neuropharmacology; 2014 Apr; 79():212-21. PubMed ID: 24291466
[TBL] [Abstract][Full Text] [Related]
18. Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Henry B; Crossman AR; Brotchie JM
Exp Neurol; 1998 Jun; 151(2):334-42. PubMed ID: 9628768
[TBL] [Abstract][Full Text] [Related]
19. Effects of single and multiple treatments with L-dihydroxyphenylalanine (L-DOPA) on dopamine receptor-G protein interactions and supersensitive immediate early gene responses in striata of rats after reserpine treatment or with unilateral nigrostriatal lesions.
Khan SM; Smith TS; Bennett JP
J Neurosci Res; 1999 Jan; 55(1):71-9. PubMed ID: 9890435
[TBL] [Abstract][Full Text] [Related]
20. DopAmide: Novel, Water-Soluble, Slow-Release l-dihydroxyphenylalanine (l-DOPA) Precursor Moderates l-DOPA Conversion to Dopamine and Generates a Sustained Level of Dopamine at Dopaminergic Neurons.
Atlas D
CNS Neurosci Ther; 2016 Jun; 22(6):461-7. PubMed ID: 26861609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
